7 results about "Substance use" patented technology

The present invention discloses a system and method for managing treatment plans and clinical documentation for substance use disorder (SUD) treatment. The system includes user devices associated with clients, clinicians, organization representatives, and supervisors. The system connects to a database storing client data, clinician data, assessment scores, and clinical documentation such as SOAP notes and progress notes. A computing device with artificial intelligence (AI) modules executes various program modules. A data collection module guides clinicians through predefined questions to gather information for generating SOAP and clinical progress notes. A secondary data collection module collects clarification from the counselor without requiring client input. A review module allows counselors to review, edit, approve, and submit documentation. A treatment plan generation module creates or updates plans based on collected data and prior scores. The system improves documentation efficiency, quality, and compliance, while supporting accurate and personalized treatment planning.

The present invention discloses a system for managing treatment of behavioral health conditions including substance use disorder (SUD). The system comprises a computing device in communication with a database and user devices via a network. The computing device provides a questionnaire comprising a plurality of categories. Each category comprises a set of questions to assess progress of the client. The computing device enables a clinician to input a score for each question based on analyzing response of client to each question. The computing device is configured to apply predefined scoring guidelines for the input score and generate the score data including the category score data for each category and the recovery score data for the questionnaire. The computing device enables the clinician to continuously evaluate and track the progress of the client, and provide a treatment plan based on current score data and progress data of the client.

Methods and compositions are disclosed for rapidly relieving symptoms in subjects with depressive, stressor and substance abuse conditions, e.g., major depression, treatment-resistant depression, post-partum depression, bipolar depression, post-traumatic stress disorder, substance use disorders, negative and cognitive symptoms of schizophrenia, as well as for slowing progression of mild cognitive impairment and dementia, using an intermittent dosing regimen of memantine or amantadine or a structural analogue or pharmaceutically acceptable salt of memantine or amantadine (optionally no more frequently than every 2 days) at a dose sufficient to activate Set A brain structures, in combination with a second drug at a dose which activates Set B brain structures but which does not appreciably evoke brain activity linked to hallucinogenic and other psychotomimetic perceptions. In some instances the second drug is either 1) a low dose psilocybin or low dose of other psychedelic and stimulant molecules capable of activating Set B of brain structures which is administered at a dose low enough such that it does not appreciably evoke brain activity linked to hallucinogenic and other psychotomimetic perceptions, or is 2) mianserin (S isomer, R isomer, or a racemate comprising both isomers or structural analog or pharmaceutically acceptable salt thereof) or another standard of care antidepressant capable of activating Set B brain structures, or 3) lumateperone or another antipsychotic capable of activating Set B brain structures.

This application provides a gene construct and its uses, which is used to inhibit neuronal overexcitation caused by the overuse or abuse of addictive substances. The gene construct comprises a neuronal inhibitory protein-coding gene and a promoter operatively linked to the neuronal inhibitory protein-coding gene. The gene construct exhibits significant advantages in precise targeting, closed-loop regulation, preservation of natural reward responses, reduced side effects and improved safety, and potential long-term efficacy and sustainability. This strategy provides new ideas and methods for the treatment of substance use disorders and is expected to become a significant breakthrough in the field of substance use disorders in the future.

The present invention relates to methods of treatment of a disease or pathology of the central nervous system, an eating disorder, or substance use disorder, drug dependence / abuse / addiction and withdrawal therefrom comprising administering at least one N-phenylalkyl amphetamine derivative and pharmaceutical compositions comprising at least one N-phenylalkyl amphetamine derivative to an individual in need thereof.

Systems and methods for managing data structures for remote monitoring and validation of user devices are described herein. A computing system can maintain a data structure including an activity field and a validation field, and determine that activity data generated in response to a user performing an activity via an application satisfies an activity condition. The computing system can update the data structure to include an activity value, and receive validation data. The computing system can update the data structure to include a validation value, and perform an operation to update a profile using a token based on the activity value and the validation value. The computing system can improve the efficacy of a medication regimen for a user condition.

The present disclosure relates to methods for treating subjects having a substance use disorder (SUD) with 4-(3-cyanophenyl)-6-pyridinylpyrimidine mGlu5 negative allosteric modulators. Specifically, in some embodiments, this disclosure relates to methods of treating a subject having SUD who is at risk of relapse to alcohol use. In some embodiments, this disclosure relates to methods of promoting remission in a subject having SUD. In some embodiments, the SUD is alcohol use disorder (AUD), opioid use disorder (OUD), or a stimulant use disorder such as cocaine use disorder (CUD).